A5007694366- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Prostate Cancer Treatment and Research
- Head and Neck Cancer Studies
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Testicular diseases and treatments
- Renal and related cancers
- Cancer Cells and Metastasis
- Cancer, Lipids, and Metabolism
- Lung Cancer Treatments and Mutations
- Salivary Gland Tumors Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Economic and Financial Impacts of Cancer
- Estrogen and related hormone effects
- Prostate Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Multiple and Secondary Primary Cancers
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
European Institute of Oncology
2014-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2023
Mylan (Switzerland)
2015-2017
Ripamonti
2012-2016
Spanish Oncology Genitourinary Group
2016
Azienda Ospedaliera Universitaria Integrata Verona
2016
University of Turin
2010
Candiolo Cancer Institute
2010
University of Milan
2003-2009
Roche (Italy)
2007
BackgroundPlatinum-based chemoradiation (CCRT) is the standard treatment for Locally Advanced Head and Neck Squamous-Cell Carcinoma (LAHNSCC). Cetuximab/RT (CET/RT) an alternative option to CCRT. The efficacy of induction chemotherapy (IC) followed by compared alone has not been demonstrated in randomized clinical trials. goals this phase II-III trial were assess: (i) overall survival (OS) IC versus no-induction (no-IC) (ii) Grade 3–4 in-field mucosal toxicity CCRT CET/RT. present paper...
The HER2/neu proto-oncogene encodes a transmembrane receptor protein involved in the development and progression of majority cancers. Prior studies have shown that oncogene is overexpressed approximately 15-30% ovarian carcinomas. However findings regarding overexpression prognosis are still conflicting.Our retrospective study was performed on 194 carcinoma tissues obtained at time first surgery. staining procedure for using polyclonal antibody.HER2/neu found 53 out (27.3%) investigated...
6004 Background: Platinum-based CRT is the standard treatment for LASCCHN. CET/RT superior to RT alone and it an alternative CRT. Induction TPF resulted be cisplatin/5fluorouracil but its efficacy when added concomitant demonstrated. We designed this open-label multicenter 2x2 factorial study assess 2 primary endpoints: 1) overall survival (OS) of induction vs. no induction; 2) Grade 3-4 in-field mucosal toxicity (already presented at ASCO 2013). Methods: 421 patients with LASCCHN oral...
The relationship between quantitative immunohistochemical hormone receptor expression and response to the combination of trastuzumab with chemotherapy in HER2-positive advanced breast cancer is currently unknown.Estrogen (ER) progesterone was studied both as a dichotomous variable (positivity set at ≥ 1% positive cells) continuous variable. effect on overall rate progression-free survival patients receiving trastuzumab-based treatment by univariate multivariate analysis.One hundred eleven...
797 Background: ARIES trial evaluated avelumab monotherapy in PD-L1+ve aUC patients (pts) not eligible to cisplatin-based chemotherapy, reaching its primary endpoint (Iacovelli R et al. ASCO-GU 2022). Treatment landscape for has changed since enfortumab-vedotin and pembrolizumab (EV+P) become the new standard platinum-eligible pts reporting also a mPFS of 10.6 mos 1-y OS rate about 80% cisplatin ineligible (carboplatin-eligible) pts. Unfortunately, up 20% are platinum-based chemotherapy...
Patients invited to take part in a clinical trial may evoke an archetype on which they base their decision of adherence participation, instead the study itself.A 17-item, multiple choice questionnaire was developed, tested and then administered 102 Italian-speaking patients with advanced lung or breast cancers who had never been exposed participation trial.The answered by all patients. Eighty-five percent were positive about participation. Demographic factors did not influence patients'...
Objective: To compare radiation-induced toxicity and dosimetry parameters in patients with locally advanced nasopharyngeal cancer (LANPC) treated a mixed-beam (MB) approach (IMRT followed by proton therapy boost) an historic cohort of full course IMRT-only.Material methods: Twenty-seven LANPC the MB were compared to similar 17 IMRT-only. The consisted first phase IMRT up 54–60 Gy second delivered boost 70–74 (RBE). total dose for IMRT-only was 69.96 Gy. Induction chemotherapy administrated...
Patients with cancer are at increased risk of complicated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but it is still unclear if the mortality influenced by type or ongoing anti-cancer treatments. An interesting debate concerning potential relationship between androgen deprivation therapy (ADT) and SARS-CoV-2 infection has recently been opened in case prostate (PC), aim this multi-centre cohort study was to investigate incidence outcomes patients metastatic...
Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. Pegylated liposomal-doxorubicin (PLD) pharmacokinetic characteristics support the rationale for using drug a metronomic fashion, potentially able to combine anthracyclines low toxicity profile.In case-series report carried out both anthracycline-naive and pre-treated cancer patients, we tested feasibility, clinical tolerability of PLD administered novel schedule 20mg/m(2) i.v. every two weeks.52 were...
6003 Background: This is the first phase III study directly comparing CRT vs CET/RT in LASCCHN. Primary endpoints of this were to compare: 1) overall survival (OS) induction vs. no arms; 2) Grade 3-4 in-field toxicity CET/RT. Preliminary results concomitant treatments (primary endpoint for comparison) reported at 2012 ASCO meeting. Here we present response rate and data two (CRT CET/RT), irrespective chemotherapy. Methods: Untreated patients with unresectable LASCCHN, stage III-IV, ECOG PS...